Fully Human Anti-CD137 Antibodies for Enhanced T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-CD137 antibodies have limitations in terms of specificity, affinity, and efficacy for stimulating immune responses, particularly in cancer treatment and immune suppression.
Innovation Solution
Development of fully human anti-CD137 antibodies with specific heavy and light chain variable domain sequences that provide high binding affinity and specificity, including IgG class antibodies, Fab fragments, and single-chain antibodies, designed to stimulate immune responses or suppress diseases effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-CD137 antibodies are used, then immune response stimulation is achieved, but specificity and affinity are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody sequence to achieve at least 95% identity to specified heavy chain variable domain sequences (SEQ ID NOs: 1-143) and light chain variable domain sequences (SEQ ID NOs: 2-128). This sequence optimization directly improves both specificity and binding affinity parameters, resolving the contradiction between these two critical properties.
2Productivity
If existing anti-CD137 antibodies are used, then some immune activation occurs, but efficacy in cancer treatment is limited
Solution Approach 1:
The patent optimizes antibody parameters by requiring at least 95% sequence identity to specified variable domains, which enhances immune response stimulation efficacy. This leads to improved T cell activation, increased CD25 expression, and better cancer treatment outcomes, directly addressing the productivity- reliability contradiction.
3Reliability
If fully human anti-CD137 antibodies with high sequence identity are developed, then specificity and affinity are improved, but development complexity increases
Solution Approach 1:
The patent establishes clear parameter thresholds (at least 95% identity to SEQ ID NOs: 1-143 for heavy chains and SEQ ID NOs: 2-128 for light chains) that provide a defined development target. This parameter-based approach simplifies the development process by providing explicit sequence criteria, reducing complexity while ensuring high specificity and affinity.
Data Source
AI summary
There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.